RxDoctor Payments Data

Matthew Nelson, MD

Gastroenterology · Grand Rapids, MINPI 1760724132

Payments from drug & device makers

$4,165in general payments, 2019–2025

Across 74 payments — averaging $56.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Boston Scientific$737
  • Olympus America Inc.$590
  • Takeda Pharmaceuticals U.S.A., Inc.$237
  • Pfizer$180
  • Medtronic$165
  • plus $381 from 10 others

What the payments were for

  • Food & beverage$4,151100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,165 in reported general payments places this provider in the 60th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$43,768
Medicare patients
192
Services billed
439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab47$601,734
Skyrizi On-BodyRisankizumab-Rzaa14$279,453
CreonLipase/Protease/Amylase21$48,706
Mesalamine28$14,727
MotegrityPrucalopride Succinate17$13,204
Balsalazide Disodium35$11,436
LinzessLinaclotide11$11,077
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg248$6,167
Azathioprine68$3,977
Budesonide DrBudesonide39$3,529
Omeprazole144$2,813
SutabSod Sulf/Pot Chloride/Mag Sulf15$2,402
Ursodiol11$2,396
Pantoprazole Sodium61$1,370
Rabeprazole Sodium46$1,315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,875$59,78332 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$237$13,20417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 497 gastroenterology providers in Michigan.

Other gastroenterology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →